Marzia Del Re, PharmD, PhD
Marzia Del Re, PharmD, PhD
Unit of Clinical Pharmacology and Pharmacogenetics, University Hospital of Pisa
Подтвержден адрес электронной почты в домене for.unipi.it
Название
Процитировано
Процитировано
Год
The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients
M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi, C Orlandini, M Miccoli, ...
European urology 71 (4), 680-687, 2017
1322017
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis
S Terrazzino, S Cargnin, M Del Re, R Danesi, PL Canonico, ...
Pharmacogenomics 14 (11), 1255-1272, 2013
1072013
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
672019
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer
P Bordi, M Del Re, R Danesi, M Tiseo
Translational lung cancer research 4 (5), 584, 2015
642015
Contribution of KRAS mutations and c. 2369C> T (p. T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
M Del Re, M Tiseo, P Bordi, A D'Incecco, A Camerini, I Petrini, M Lucchesi, ...
622016
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
M Del Re, R Marconcini, G Pasquini, E Rofi, C Vivaldi, F Bloise, ...
BRITISH JOURNAL OF CANCER, 1-5, 2018
602018
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity
A Di Paolo, G Bocci, M Polillo, M Del Re, T Di Desidero, M Lastella, ...
Current drug metabolism 12 (10), 932-943, 2011
592011
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
R Minari, P Bordi, M Del Re, F Facchinetti, F Mazzoni, F Barbieri, ...
Lung Cancer 115, 21-27, 2018
492018
Clinical pharmacology of intravitreal anti-VEGF drugs
S Fogli, M Del Re, E Rofi, C Posarelli, M Figus, R Danesi
Eye 32 (6), 1010, 2018
422018
Pharmacogenetics of anti-estrogen treatment of breast cancer
M Del Re, A Michelucci, P Simi, R Danesi
Cancer treatment reviews 38 (5), 442-450, 2012
412012
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema
S Fogli, S Mogavero, CG Egan, M Del Re, R Danesi
Pharmacological research 103, 149-157, 2016
392016
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight
G Aprile, E Ongaro, M Del Re, SE Lutrino, M Bonotto, L Ferrari, K Rihawi, ...
Critical Reviews in Oncology/Hematology 95 (2), 165-178, 2015
362015
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer
M Santoni, F Massari, M Del Re, C Ciccarese, F Piva, G Principato, ...
Expert Opinion on Investigational Drugs 24 (6), 809-824, 2015
352015
Genetic variation: effect on prostate cancer
TM Sissung, DK Price, M Del Re, AM Ley, E Giovannetti, WD Figg, ...
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (2), 446-456, 2014
352014
Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment
E Arrigoni, M Del Re, S Galimberti, G Restante, E Rofi, S Crucitta, ...
Stem cells translational medicine 7 (3), 305-314, 2018
332018
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
M Del Re, V Citi, S Crucitta, E Rofi, F Belcari, RH Van Schaik, R Danesi
Pharmacological research 107, 398-406, 2016
332016
Real‐Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2V617F mutation in Philadelphia‐negative chronic myeloproliferative neoplasms
G Fontanelli, C Baratè, E Ciabatti, F Guerrini, S Grassi, M Del Re, ...
International Journal of Laboratory Hematology 37 (6), 766-773, 2015
302015
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.
M Del Re, C Vivaldi, E Rofi, E Vasile, M Miccoli, C Caparello, P d'Arienzo, ...
Sci Rep. 7 (1), 7931, 2017
272017
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of …
G Roviello, S Sigala, R Danesi, M Del Re, A Bonetta, MR Cappelletti, ...
Critical Reviews in Oncology/Hematology 101, 12-20, 2016
272016
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer
S Sameen, R Barbuti, P Milazzo, A Cerone, M Del Re, R Danesi
Journal of theoretical biology 389, 263-273, 2016
262016
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20